Cardinal Health reported a stronger fiscal fourth quarter on profit but missed revenue expectations, as adjusted diluted EPS rose 40% to $2.91 and topped the $2.42 analyst consensus while revenue increased 6% to $63.67 billion, below forecasts near $65.1 billion. The company said adjusted EPS included a $0.31-per-share benefit from tariff-related refunds tied to IEEPA trade measures, putting core fourth-quarter adjusted EPS at $2.60. GAAP net earnings rose to $398 million, or $1.70 per share, from $239 million, or $1.00 per share, and non-GAAP operating earnings increased 30% to $935 million. Cardinal Health forecast fiscal 2027 adjusted EPS of $12.40 to $12.60, above analyst expectations around $12.08, with pharmaceutical revenue growth of 3% to 5% and Global Medical Products and Distribution growth of 2% to 4%. The pharmaceutical business drove quarterly growth with higher volumes from existing customers and strong generic sales, while the medical products and distribution unit posted a 2% sales decline tied to lower distribution activity and the accounting effect of expected tariff refund reimbursements to customers. The outlook includes the completed Strive Medical acquisition and the planned purchase of AdaptHealth's diabetes operations. Cardinal Health also said it put in place a new $4 billion revolving credit facility maturing in 2031 and declared a quarterly dividend of $0.5158 per share payable on October 15, 2026 to shareholders of record on October 1, 2026.